Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Comupter Game - 2The Solution to Individual budget: Dominating Cash The board
- 3Figure out How to Clean and Really focus on Your Lab Jewel
- 4Daily Briefing: A bad flu season gets worse
- 5The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Massive supernova explosion may have created a binary black hole
- ‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Reviving Your Home with Nutritious Indoor Plants
- The race to mine the moon is on – and it urgently needs some clear international rules
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
